S1PR5: IHC Expression in Cancer and Radioligand Target Profile
S1PR5, sphingosine-1-phosphate receptor 5, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, S1PR5 staining is highest in liver cancer (67% of samples positive), prostate cancer (18% of samples positive) and thyroid cancer (25% of samples positive). Evidence on whether S1PR5 internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is S1PR5 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze S1PR5 freeIs S1PR5 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in liver cancer, 67% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
S1PR5 IHC staining by cancer type
Protein expression of S1PR5 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Liver Cancer | 0.64 | High | 67% |
| Prostate Cancer | 0.09 | Low | 18% |
| Thyroid Cancer | 0.08 | Low | 25% |
| Cervical Cancer | 0.08 | Low | 17% |
| Glioma | 0.08 | Low | 17% |
| Ovarian Cancer | 0.06 | Low | 17% |
| Colorectal Cancer | 0.06 | Low | 8% |
| Breast Cancer | 0.03 | Low | 8% |
| Bladder Cancer | 0.03 | Low | 8% |
| Lung Cancer | 0.03 | Low | 8% |
Not detected by IHC in: skin cancer, head and neck cancer, lymphoma, melanoma, kidney cancer, neuroendocrine tumors, pancreatic cancer, gastric cancer, testicular cancer, endometrial cancer.
Is S1PR5 internalized?
Uncertain. Insufficient literature found.
Sources: PMID 41824554 · PMID 40911968 · PMID 38798480 · PMID 33983615 · PMID 29733947. AI-extracted from abstracts, so verify before citing.
S1PR5 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for S1PR5 yet. Search ClinicalTrials.gov for S1PR5 trials.
S1PR5 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See S1PR5 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
S1PR5 gene essentiality (DepMap)
CRISPR knockout effect across 1255 cancer cell lines: 0.05 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related liver cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · STEAP2 · HER2 (ERBB2) · Mesothelin (MSLN) · B7-H3 (CD276)
See all radioligand therapy targets in liver cancer.
See how S1PR5 ranks against 15,000 targets for your indication.
Analyze S1PR5 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.